miR-122 was down-regulated in IS, representing a potential biomarker and target for the prevention and treatment of IS.[17,18] Elevating miR-122 can improve stroke outcomes via down-regulating its target genes.[19] To date, IL-1A rs3783553 has been investigated in varieties of human diseases, including hepatocellular carcinoma,[16] papillary thyroid carcinoma,[20] endometriosis,[21,22] preeclampsia,[23] osteoarthritis,[24] hepatitis B,[25] and nonalcoholic fatty liver disease.[26] However, no data about the relationship between IL-1A rs3783553 and the risk of IS were reported. This evidence concerns the gene IL1A and metabolic dysfunction-associated steatotic liver disease.